Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Half of the study participants will get tablets containing semaglutide and half will get inactive placebo tablets which look like the semaglutide tablets but have no active drug in them.

At the end of the study we will see how many people in each group suffered a serious heart or circulation problem. These conditions include:

  • heart attacks, strokes or mini strokes (also known as transient ischaemic attacks or TIA)
  • death from heart or circulatory problems
  • the need for a stent or bypass surgery to treat a blocked heart artery.

This information will be analysed to find out if oral semaglutide truly does reduce the risk of people with type 2 diabetes developing these conditions.

Oral semaglutide could also potentially reduce the risk of people with type 2 diabetes from developing other health problems related to diabetes, such as kidney disease and long-term memory problems including dementia. The ASCEND PLUS research team will investigate this.